BioCentury
ARTICLE | Clinical News

Exelon Patch rivastigmine neurology data

July 24, 2006 7:00 AM UTC

Data from the 6-month, double-blind, placebo-controlled, international IDEAL study in 1,195 patients showed that NVS's Exelon Patch led to significant improvements in memory versus placebo. Also, Exel...